lumefantrine plus artemether — Competitive Intelligence Brief

lumefantrine plus artemether (lumefantrine plus artemether) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination therapy. Area: Infectious Disease.

marketed Antimalarial combination therapy Malaria parasite heme metabolism and hemozoin formation Infectious Disease Small molecule

Target snapshot

lumefantrine plus artemether (lumefantrine plus artemether) — Centers for Disease Control and Prevention. Lumefantrine and artemether work together as antimalarial agents that kill malaria parasites through distinct mechanisms involving heme detoxification and rapid parasite clearance.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
lumefantrine plus artemether TARGET	lumefantrine plus artemether	Centers for Disease Control and Prevention	marketed	Antimalarial combination therapy	Malaria parasite heme metabolism and hemozoin formation
SP-IPTp	SP-IPTp	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum dihydrofolate reductase (sulfadoxine-pyrimethamine); hemozoin formation (piperaquine)
Artesunate plus Amodiaquine	Artesunate plus Amodiaquine	Bernhard Nocht Institute for Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum (multiple parasite targets including heme detoxification pathway and DNA synthesis)
Coadministered Artesunate plus Amodiaquine	Coadministered Artesunate plus Amodiaquine	Professor Anders Björkman	marketed	Antimalarial combination therapy	Plasmodium falciparum heme metabolism and protein synthesis
Amodiaquine-artesunate (ASAQ)	Amodiaquine-artesunate (ASAQ)	Centers for Disease Control and Prevention	marketed	Antimalarial combination therapy	Plasmodium falciparum heme polymerase; artemisinin-derived endoperoxide bridge
WHO-recommended periodic presumptive treatment	WHO-recommended periodic presumptive treatment	University of Washington	marketed	Antimalarial combination therapy
IPTp-DP	IPTp-DP	Kenya Medical Research Institute	marketed	Antimalarial combination therapy	Plasmodium falciparum (malaria parasite)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination therapy class)

1. London School of Hygiene and Tropical Medicine · 4 drugs in this class
2. Kenya Medical Research Institute · 2 drugs in this class
3. University of Oxford · 2 drugs in this class
4. Centers for Disease Control and Prevention · 2 drugs in this class
5. University of Melbourne · 1 drug in this class
6. Bernhard Nocht Institute for Tropical Medicine · 1 drug in this class
7. University of Washington · 1 drug in this class
8. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
9. Medicines for Malaria Venture · 1 drug in this class
10. Professor Anders Björkman · 1 drug in this class